IP Library Granted Patent US 9,463,231
Granted Patent B2
US 9,463,231 · App. 14/447,694 · Granted Oct 11, 2016

Immunogenic compositions comprising

Inventors: Jeremy Kroll (Urbandale, IA); Mike Roof (Ames, IA)
Assignee: Boehringer Ingelheim Vetmedica, Inc.
A61K39/105A61K39/0241A61K39/0275A61K35/74A61K39/295A61K39/39A61K2039/522A61K2039/542A61K2039/55A61K2039/552A61K2039/70Y10S424/825
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,463,231
App. No.
14/447,694
Granted
Oct 11, 2016
Kind
B2
Abstract

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

Claims (9)

1. A pharmaceutical composition comprising antigens which consist essentially of:

i. killed Lawsonia intracellularis bacterium,

ii. killed Mycoplasma hyopneumoniae , and

iii. Porcine circovirus.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically-acceptable carrier.

3. The pharmaceutical composition of claim 2 , wherein the pharmaceutically-acceptable carrier is an adjuvant.

4. The pharmaceutical composition of claim 3 , wherein said adjuvant is selected from the group of water-in-oil emulsion, oil-in-water emulsion or water-in-oil-in-water emulsion.

5. The pharmaceutical composition of claim 1 , wherein the quantity of immunogen will be between 5 and 5000 micrograms.

6. The pharmaceutical composition of claim 1 , wherein said Porcine circovirus is the immunological active part.

Assignments (2)
MERGER Recorded May 22, 2019
From: BOEHRINGER INGELHEIM VETMEDICA, INC.
To: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Reel/Frame 049257/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2018
From: KROLL, JEREMY; ROOF, MIKE
To: BOEHRINGER INGELHEIM VETMEDICA, INC.
Reel/Frame 047439/0079 →
Continuity (3)
Continuation 11374350 · Mar 13, 2006
Provisional Application 60661352 · Mar 14, 2005
Related Publication 20140341947A1 · Nov 20, 2014